- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00860808
Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus
Efficacy of AM 101 in Patients With Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II Study
Study Overview
Detailed Description
Tinnitus may seriously impact the ability to sleep, relax, or to concentrate, or lead to tiredness, irritation, nervousness, despair, frustration, or depression, thus severely impacting the quality of life and health of the affected person. To date, there exists no pharmaceutical treatment for persisting tinnitus.
Non-clinical studies with AM-101 have shown that the inhibition of cochlear NMDA receptors is successful in suppressing tinnitus without affecting normal glutamate neurotransmission respectively hearing function. In particular, it could be demonstrated that local administration of AM-101 in a single dose resulted in a complete suppression of tinnitus induced by acute acoustic trauma without any relapse thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Ulm, Germany, 89081
- Bundeswehrkrankenhaus Ulm
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Persistent tinnitus following acute acoustic trauma, sudden deafness, or acute otitis media with onset less than three months ago (i.e. acute tinnitus)
- Tinnitus provoking incident of acute acoustic trauma, sudden deafness or acute otitis media is documented by audiogram and medical report and at onset resulted in an inner ear hearing loss of at least 15 dB in two adjacent frequencies
- Minimum Masking Level (MML) of at least 5 dB SL
- Age ≥ 18 years and ≤ 65 years
- Negative pregnancy test for women of childbearing potential
- Willing and able to attend the on-study visits
- Must be able to read and understand the relevant study documents
- Written informed consent before participation in the study
Exclusion Criteria:
- Tinnitus that is not completely maskable
- Fluctuating tinnitus
- Intermittent tinnitus
- Meniere's Disease
- Acute or chronic otitis media or otitis externa
- Any ongoing therapy known as potentially tinnitus-inducing (e.g. aminoglycosides, cisplatin, loop diuretics, high doses of aspirin, quinine etc.)
- Any drug-based therapy for inner ear hearing loss that is ongoing or was performed in the past 2 weeks, e.g. prednisolone, dexamethasone, pentoxifylline, betahistine, diazepam, carbamazepine, sodium valproate and antidepressants
- Concomitant use of any other NMDA receptor antagonist (e.g. memantine, dextromethorphan, ifenprodil)
- Any ongoing or planned concomitant medication for the treatment of tinnitus until 90 days after study drug application
- History or presence of drug abuse or alcoholism
- Any clinically relevant respiratory, cardiovascular, neurological (except vertigo), or psychiatric disorder
- Known hypersensitivity, allergy or intolerance to the study medication or any history of severe abnormal drug reaction
- Women who are breast-feeding, pregnant or who plan a pregnancy during the trial
- Women of childbearing potential who declare being unwilling or unable to practice contraception such as hormonal contraceptives, sexual abstinence or intercourse with a vasectomised partner
- Concurrent participation in another clinical trial with an investigational drug or participation in another clinical trial with an investigational drug within 30 days prior to study entry
- Any drug-based therapy for otitis media that is ongoing or was performed in the past 2 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 AM-101
low dose
|
Triple intratympanic injection (one on each day 1, 2, and 3)
|
Experimental: 2 AM-101
high dose
|
Triple intratympanic injection (one on each day 1, 2, and 3)
|
Placebo Comparator: 3 Placebo
|
Triple intratympanic injection (one on each day 1, 2, and 3)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the minimum masking level from Baseline to Day 90
Time Frame: Day 90
|
Day 90
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Standard audiological evaluations
Time Frame: D7, D30, D90
|
D7, D30, D90
|
Questionaires evaluating the impact of tinnitus
Time Frame: D7, D30, D90
|
D7, D30, D90
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Heinz Maier, MD, Bundeswehrkrankenhaus Ulm
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AM-101-CL-08-01
- EudraCT number: 2008-005178-10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinnitus
-
State University of New York at BuffaloUniversity at BuffaloCompletedTinnitus, Subjective | Tinnitus | Noise Induced Tinnitus | Tinnitus, Objective | Tinnitus Aggravated | Tinnitus, Pulsatile | Tinnitus, Spontaneous Oto-Acoustic Emission | Tinnitus, Clicking | Tinnitus, Tensor Tympani InducedUnited States
-
Mohab MohammedNot yet recruitingPulsatile Tinnitus (Diagnosis)
-
Philipps University Marburg Medical CenterLinkoeping University; Eriksholm Research Centre; University Hospital of Gießen...CompletedTinnitus | Subjective Tinnitus | Chronic TinnitusGermany
-
University of GuadalajaraHospital Civil de Guadalajara; Institute of Experimental and Clinical TherapeuticsRecruitingOxidative Stress | Tinnitus, Subjective | Tinnitus, Bilateral | Antioxidant Therapy | Psychiatric Drugs | Inflammatory Cytokines | SSRIMexico
-
University Hospital, BordeauxNot yet recruiting
-
Cairo UniversityRecruiting
-
University of ZurichRecruitingTinnitus, Subjective | TinnitusSwitzerland
-
Eye & ENT Hospital of Fudan UniversityNot yet recruiting
-
University of Illinois at Urbana-ChampaignGN Hearing A/SActive, not recruitingTinnitus, SubjectiveUnited States
-
University of ZurichCompletedTinnitus, SubjectiveGermany, Switzerland
Clinical Trials on AM-101
-
Auris Medical AGCompleted
-
Auris Medical, Inc.Completed
-
Auris Medical, Inc.Completed
-
Auris Medical, Inc.CompletedTinnitusUnited States, Germany, Belgium, Poland
-
Istanbul University - Cerrahpasa (IUC)Not yet recruitingSleep Quality | Mother-Infant Interaction | AttachmentTurkey
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingHealthy | Overweight and ObesityUnited States
-
AllerganCompletedBlue Light DamageUnited States
-
Providence HealthcareCompletedRehabilitation | Psychological Distress | Psychological StressCanada
-
Auris Medical AGCompleted